证券代码：301234 证券简称：五洲医疗 编号：2022-001 安徽宏宇五洲医疗器械股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|---------------------------------------------------------|-----------------------------------------------------------------------------| | 投资者关系 \n活动类别 | ☑ 特定对象调研 \n□ 媒体采访 \n□ 新闻发布会 \n□ 现场参观 | □ 分析师会议 \n□ 业绩说明会 \n□ 路演活动 \n□ 其他（请文字说明其他活动内容） | | | 张金涛 | 华宝基金管理有限公司 | | 参与单位名称 | 齐 震 | 华宝基金管理有限公司 | | 及人员姓名 | 魏扬帆 | 华宝基金管理有限公司 | | | 李乾宁 | 工银瑞信基金管理有限公司 | | 时 间 | 2022 年 8 | | | 地 点 | 网络方式 | | | | 黄 凡 | | | 上市公司 ...

证券代码：301234 证券简称：五洲医疗 编号：2022-002 安徽宏宇五洲医疗器械股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------------|-------|---------------------------|--------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

安徽宏宇五洲医疗器械股份有限公司 安徽宏宇五洲医疗器械股份有限公司 2022 年第三季度报告 证券代码：301234 证券简称：五洲医疗 公告编号：2022-013 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 重要内容提示： 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财 务信息的真实、准确、完整。 3、第三季度报告是否经过审计 □是 否 1 安徽宏宇五洲医疗器械股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 比上年同期增减 | | 营业收入（元） | 147,385,573.73 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2022, representing a year-on-year increase of 15%[18]. - The net profit attributable to shareholders was 80 million CNY, up 20% compared to the same period last year[18]. - The company's operating revenue for the first half of 2022 was CNY 248.62 million, an increase of 11.75% compared to CNY 222.49 million in the same period last year[34]. - The net profit attributable to shareholders was CNY 31.47 million, reflecting a growth of 12.63% from CNY 27.94 million year-on-year[34]. - The gross margin for the first half of 2022 improved to 45%, up from 40% in the same period last year, indicating better cost management[44]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion CNY for the first half of 2022, representing a year-over-year growth of 20%[44]. - The company has provided a positive outlook for the second half of 2022, projecting a revenue increase of 15% to 1.725 billion CNY[44]. - The total operating revenue for the first half of 2022 reached CNY 248.62 million, an increase of 11.7% compared to CNY 222.49 million in the same period of 2021[164]. - Net profit for the first half of 2022 was CNY 31.47 million, representing a 12.1% increase from CNY 27.94 million in the first half of 2021[165]. Market Expansion and Strategy - User data indicates a growth in active users by 25%, reaching 1.5 million users by the end of June 2022[18]. - The company plans to launch two new medical devices in Q4 2022, aiming to capture a 10% market share in the new segments[18]. - The company is focusing on expanding its market presence in Southeast Asia, targeting a 5% market penetration by the end of 2023[18]. - The company is expanding its market presence by entering new regions, targeting a 10% market share in Southeast Asia by the end of 2023[45]. - The company has initiated a strategic acquisition of a local competitor, which is expected to enhance its product portfolio and increase market share by 5%[46]. - The company has established partnerships with three major hospitals to enhance product distribution and increase brand visibility[45]. Research and Development - Research and development expenses increased by 30% to 50 million CNY, reflecting the company's commitment to innovation[18]. - The company continues to focus on the research and development of disposable sterile infusion medical devices, maintaining a competitive edge in the medical consumables market[32]. - Research and development investments have increased by 25% compared to the previous year, focusing on innovative medical device technologies[44]. - The company has built a comprehensive technical R&D and quality assurance system, focusing on the disposable sterile infusion medical consumables sector[48]. - The company is focusing on enhancing its research and development capabilities to innovate new technologies in the medical device sector[180]. Financial Health and Investments - The net cash flow from operating activities increased significantly by 70.45%, reaching CNY 58.98 million compared to CNY 34.60 million in the previous year[34]. - Total assets at the end of the reporting period amounted to CNY 834.46 million, a substantial increase of 117.84% from CNY 383.07 million at the end of the previous year[34]. - The net assets attributable to shareholders rose by 160.30% to CNY 683.99 million from CNY 262.77 million at the end of the previous year[34]. - The company has established a stable customer resource network, covering over 80 countries and regions, including Europe, Asia, and America[52]. - The company has achieved a stable supply capability through strong R&D design and long-term manufacturing experience, with a focus on automation in production processes[51]. - The company raised RMB 423,433,361.01 from its initial public offering, marking a significant increase of 3,297.72% compared to the previous period[55]. - Cash and cash equivalents increased to RMB 430,236,821.40, reflecting a growth of 4,966.85% due to the funds received from the IPO[55]. Regulatory and Risk Management - The management highlighted risks related to regulatory changes and supply chain disruptions, with strategies in place to mitigate these risks[18]. - The company faces risks from intensified market competition, which could lead to a decline in market share if competitive capabilities are not enhanced[82]. - Fluctuations in raw material prices, particularly for polyethylene and polypropylene, could significantly impact production costs and profits[84]. - The company has established a comprehensive quality management system in compliance with various international standards to mitigate product quality control risks[91]. - The company will monitor exchange rate fluctuations and engage in forward foreign exchange transactions to mitigate currency risk[93]. Environmental and Social Responsibility - The company has implemented pollution prevention facilities that operate normally, with no environmental pollution incidents reported during the reporting period[104]. - The company has committed to low-carbon sustainable development, optimizing product design and manufacturing processes to reduce material and energy consumption[109]. - The company created over 700 job opportunities in the local area, contributing to rural revitalization efforts[112]. - The company donated 1,000 sets of living supplies to support pandemic prevention efforts during a severe outbreak in East China[112]. Shareholder Information - The company reported a total of 51 million shares before the recent issuance, which increased to 68 million shares after the issuance of 17 million new shares[140]. - The issuance of 17 million shares was approved by the China Securities Regulatory Commission on May 17, 2022, and the shares were listed on July 5, 2022[141]. - The largest shareholder, Huang Fan, holds 24.16% of the shares, amounting to 16,429,650 shares[145]. - The second-largest shareholder, Xiang Bingyi, holds 20.25% of the shares, totaling 13,770,000 shares[145]. - The company has not reported any changes in accounting policies or prior period error corrections during this reporting period[183].